Finance
Rectogesic maker announces third-quarter net loss of $2,793,000
Published in AIDS Weekly, December 12th, 2005
Cellegy had a net loss of $3,143,000 or $0.14 per basic and diluted common share during the same period in 2004. Cellegy's cumulative net loss for the 9-month period in 2005 was $3,044,000 or $0.11 per basic and diluted common share compared to a net loss of $8,909,000 or $0.43 per common share during the same period last year.
Revenues for the quarters ended September 30, 2005 and 2004 were $1,952,000 and $483,000, respectively. For the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-12-12)
More Articles from AIDS Weekly
- HIV/AIDS Diagnostics
HIV phenotypic resistance testing may help interpret unclear genotype results - HIV/AIDS-Associated Peripheral Neuropathy
Mitochondrial haplogroup T more frequent in NRTI-associated peripheral neuropathy - HIV/AIDS-Related Lipodystrophy
Puberty is independently associated with metabolic disturbances risk in HIV-infected children - Adenovirus Diagnostics
PCR-based assay quantifies and genotypes all known adenovirus serotypes - Complementary & Alternative Medicine
Parents often use CAM in their healthy, asthmatic, or HIV-infected children - Drug Resistance
The associations between MRSA infection and HIV severity indicators merit examination - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
